▶ Manufacturer: Ilhwa Co., Ltd.
▶ Sold by: Ilhwa Co., Ltd.
▶ Insurance code : A06502551
▶ Storage : Airtight container, store at room temperature (1 to 30℃)
White to white-grey rounded cylindrical tablet
pioglitazone hydrochloride 16.53mg
This drug is administered once a day regardless of meals.
Management of diabetes must be carried out on an individualized basis. Ideally, response to treatment should be evaluated by observing glycated hemoglobin (HbA1c) levels instead of fasting blood glucose (FBG). Glycated hemoglobin reflects blood glucose levels over the past 2 to 3 months. Clinically, if blood glucose regulation is not worsened in a diabetes patient, the drug needs to be administered for a period adequate for evaluating changes in glycated hemoglobin levels (3 months at minimum). No data on use on children below 18 years of age; administration is not recommended.
1. Single therapy
Administration of this drug to patients whose blood glucose is not adequately regulated by dietary and exercise therapy may be started at 15mg pioglitazone once a day in single therapy. If sufficient effects are not obtained with the starting dose of this drug, the dose may be increased up to 30mg once a day. Concomitant therapy should be considered for patients who do not respond sufficiently to single therapy.
2. Concomitant therapy
1) Sulfonylurea: This drug may be administered concomitantly with sulfonylurea drugs, at an initial dose of 15mg once a day. When used in concomitant therapy with this drug, the current sulfonylurea drug may be continued with the same method and dose of administration.
If the patient exhibits hypoglycemic symptoms, the dose of sulfonylurea must be reduced.
2) Metformin: This drug may be administered concomitantly with metformin drugs, at an initial dose of 15mg once a day. When used in concomitant therapy with this drug, the current metformin drug may be continued with the same method and dose of administration. It is expected there will be no need to adjust metformin dose due to hypoglycemic symptoms during concomitant therapy with this drug.
This drug is administered as a supplement to dietary and exercise therapy to improve blood glucose regulation of Type II diabetes patients.
1. This drug is administered in single therapy.
2. This drug is administered in concomitant therapy in the following cases:
Concomitant administration with sulfonylurea drugs, metformin or insulin if hypoglycemic effect was not achieved despite using other oral hypoglycemics
Type II diabetes patients also require nutritional consulting, as well as weight loss and exercise therapy in some cases. Such efforts on the part of Type II diabetes patients are important not only for early treatment but to maintain the effectiveness of drug therapy.White to white-grey rounded cylindrical tablet
pioglitazone hydrochloride 16.53mg
This drug is administered once a day regardless of meals.
Management of diabetes must be carried out on an individualized basis. Ideally, response to treatment should be evaluated by observing glycated hemoglobin (HbA1c) levels instead of fasting blood glucose (FBG). Glycated hemoglobin reflects blood glucose levels over the past 2 to 3 months. Clinically, if blood glucose regulation is not worsened in a diabetes patient, the drug needs to be administered for a period adequate for evaluating changes in glycated hemoglobin levels (3 months at minimum). No data on use on children below 18 years of age; administration is not recommended.
1. Single therapy
Administration of this drug to patients whose blood glucose is not adequately regulated by dietary and exercise therapy may be started at 15mg pioglitazone once a day in single therapy. If sufficient effects are not obtained with the starting dose of this drug, the dose may be increased up to 30mg once a day. Concomitant therapy should be considered for patients who do not respond sufficiently to single therapy.
2. Concomitant therapy
1) Sulfonylurea: This drug may be administered concomitantly with sulfonylurea drugs, at an initial dose of 15mg once a day. When used in concomitant therapy with this drug, the current sulfonylurea drug may be continued with the same method and dose of administration.
If the patient exhibits hypoglycemic symptoms, the dose of sulfonylurea must be reduced.
2) Metformin: This drug may be administered concomitantly with metformin drugs, at an initial dose of 15mg once a day. When used in concomitant therapy with this drug, the current metformin drug may be continued with the same method and dose of administration. It is expected there will be no need to adjust metformin dose due to hypoglycemic symptoms during concomitant therapy with this drug.
This drug is administered as a supplement to dietary and exercise therapy to improve blood glucose regulation of Type II diabetes patients.
1. This drug is administered in single therapy.
2. This drug is administered in concomitant therapy in the following cases:
Concomitant administration with sulfonylurea drugs, metformin or insulin if hypoglycemic effect was not achieved despite using other oral hypoglycemics
Type II diabetes patients also require nutritional consulting, as well as weight loss and exercise therapy in some cases. Such efforts on the part of Type II diabetes patients are important not only for early treatment but to maintain the effectiveness of drug therapy.
